TYSABRI (natalizumab): Reviews and patient testimonials
Medication indications
TYSABRI 300 mg concentrate for solution for infusion
TYSABRI is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:
• Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1)
or
• Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.
Route of administration: Injectable
Molecule: natalizumab
Patients' opinions on TYSABRI
In brief
General satisfaction level: 9.25/10 Learn more
Treatment's effectiveness: 9.50/10 Learn more
Ease of use: 8.00/10 Learn more
Adherence to prescription: 10.00/10 Learn more
Detected side effects: 1.50/10 Learn more
Improvement in the quality of life: 8.25/10 Learn more
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Not at all satisfied
10 = Extremely satisfied
1 = Never
10 = Always
1 = Not at all important
10 = Extremely important
1 = Not at all satisfied
10 = Extremely satisfied
Tips and advice of the community